Log in

Relevant bibliographies by topics / IPI (Association) / Journal articles

To see the other types of publications on this topic, follow the link: IPI (Association).

Journal articles on the topic 'IPI (Association)'

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'IPI (Association).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Postow, Michael Andrew, Scott D. Chasalow, Jianda Yuan, et al. "Pharmacodynamic effect of ipilimumab on absolute lymphocyte count (ALC) and association with overall survival in patients with advanced melanoma." Journal of Clinical Oncology 31, no. 15_suppl (2013): 9052. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.9052.

Full text

Abstract:

9052 Background: Ipilimumab (Ipi) is a fully human monoclonal antibody that augments antitumor T-cell responses. Ipi has been shown to improve overall survival (OS) in 2 phase (ph) III trials of advanced melanoma, as monotherapy at 3 mg/kg in previously treated patients (pts) (MDX010-20) or at 10 mg/kg with dacarbazine in previously untreated pts (CA184-024). In preclinical and clinical studies, inhibition of CTLA-4 by Ipi resulted in increases in activation and proliferation of peripheral T cells and increases in ALC. Baseline ALC may be a prognostic biomarker in several cancer types. The cur

APA, Harvard, Vancouver, ISO, and other styles

2

Avilia, Vivi, Vita Amelia, and Hadira Latiar. "PERAN IKATAN PUSTAKAWAN INDONESIA (IPI) PROVINSI RIAU DALAM MENGEMBANGKAN KUALITAS SUMBER DAYA MANUSIA PUSTAKAWAN." Fihris: Jurnal Ilmu Perpustakaan dan Informasi 15, no. 1 (2020): 115. http://dx.doi.org/10.14421/fhrs.2020.151.115-130.

Full text

Abstract:

The Indonesian Librarian Association (IPI) Organization of Riau Province is one of the organizations that support the quality of human resources in the librarian profession, with the existence of a professional librarians organization can help librarians in improving library management to the maximum. This study aims to determine how the Role of the Indonesian Librarian Association (IPI) of Riau Province in Developing the Quality of Librarian Human Resources. The method used in this research is descriptive qualitative research method. This research was conducted by interviewing the management

APA, Harvard, Vancouver, ISO, and other styles

3

SADIA ILYAS, FARZANA LATIF, and NAILA YASMEEN. "ASSOCIATION OF SHORT INTER-PREGNANCY INTERVAL WITH ADVERSE PERINATAL OUTCOME." Pakistan Postgraduate Medical Journal 26, no. 1 (2015): 11–17. http://dx.doi.org/10.51642/ppmj.v26i1.173.

Full text

Abstract:

Background: The time interval in between pregnancies is viewed as an important and modifiable risk factor for adverse birth outcome. Short interpregnancy interval is associated with a number of adverse outcome for both mother and child, including increased risk of preterm labour, low birth weight baby, and preeclampsia . Objective: To determine the association between adverse perinatal outcome and short inter-pregnancy interval in women presenting in labour Material and Methods: This cohort study was conducted at department of Obstetrics and Gynaecology, unit 1, Lahore General Hosp

APA, Harvard, Vancouver, ISO, and other styles

4

Hu, Xuan, Ying Yang, Long Wang, et al. "Interpregnancy Interval After Healthy Live Birth and Subsequent Spontaneous Abortion." JAMA Network Open 7, no. 6 (2024): e2417397. http://dx.doi.org/10.1001/jamanetworkopen.2024.17397.

Full text

Abstract:

ImportanceMany studies have reported that the interpregnancy interval (IPI) is a potential modifiable risk factor for adverse perinatal outcomes. However, the association between IPI after live birth and subsequent spontaneous abortion (SA) is unclear.ObjectiveTo investigate the association of IPI after a healthy live birth and subsequent SA.Design, Setting, and ParticipantsThis prospective cohort study used data from 180 921 women aged 20 to 49 years who had a single healthy live birth and planned for another pregnancy and who participated in the Chinese National Free Prepregnancy Checkups Pr

APA, Harvard, Vancouver, ISO, and other styles

5

Gopaluni, Srivalli, Neerja Vajpayee, Nancy Newman, Charu Thakral, Juhi Husain, and Ajeet Gajra. "Expression of mTOR in diffuse large B-cell lymphoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): e18535-e18535. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e18535.

Full text

Abstract:

e18535 Background: The mammalian target of rapamycin (mTOR) pathway mediates protein synthesis, cell growth and survival of normal and malignant cells. This pathway is constitutively activated in several B-cell lymphomas. We studied immunohistochemical expression of mTOR, phosphorylated mTOR (pmTOR) and bcl-2 in 55 cases of diffuse large B-cell lymphomas (DLBCL) and their association with established prognostic factors as well as treatment outcomes in a retrospective single instituition study. Methods: After IRB review, 55 cases of DLBCL were identified. Immunostains for mTOR, pmTOR and bcl-2

APA, Harvard, Vancouver, ISO, and other styles

6

Obermayer, Alyssa N., Timothy I. Shaw, Sandra J. Lee, et al. "Abstract 5704: An integrated immune signature predictive of adjuvant immunotherapeutic benefits for high-risk melanoma." Cancer Research 83, no. 7_Supplement (2023): 5704. http://dx.doi.org/10.1158/1538-7445.am2023-5704.

Full text

Abstract:

Abstract Introduction CTLA4 blockade with ipilimumab was more favorable than interferon-α2b (IFN) in high-risk melanoma in phase adjuvant III trial E1609. Characterization of the pretreatment tumor immune biomarkers and clinical covariates may inform the likelihood of response to ipilimumab and other immune checkpoint inhibitors (ICI), and guide future development of this and other modalities in this patient population. Methods We utilized PATH-SURVEIOR, a bioinformatics framework developed in-house for associating genes and pathway signatures with clinical endpoints, to perform survival analy

APA, Harvard, Vancouver, ISO, and other styles

7

Gaytán-González, Alejandro, María de Jesús Ocampo-Alfaro, Maritza Arroniz-Rivera, et al. "Inadequate Protein Intake at Specific Meals Is Associated with Higher Risk of Impaired Functionality in Middle to Older Aged Mexican Adults." Journal of Aging Research 2019 (April 4, 2019): 1–8. http://dx.doi.org/10.1155/2019/6597617.

Full text

Abstract:

Purpose. To describe the proportions of inadequate protein intake (IPI) per day and per meal and their association with functionality in middle to older aged Mexican adults. Materials and Methods. In a cross-sectional design, we evaluated the protein intake and functionality of instrumental activities of daily living (IADL) and activities of daily living (ADL) of 190 middle to older aged Mexican adults. IPI was considered as any protein intake: <1.2 g/kg/day, <30 g/meal, or <0.4 g/kg/meal. Functionality was organized into three groups: high, middle, and low scores. The first was set a

APA, Harvard, Vancouver, ISO, and other styles

8

Druyts, Eric, Mark Boye, Himani Agg, Catherine Muehlenbein, Andrew Frederickson, and Theresa Bayt. "Immune-related adverse events and efficacy outcomes in patients treated with immunotherapy: A systematic review and meta-analysis." Journal of Clinical Oncology 38, no. 5_suppl (2020): 92. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.92.

Full text

Abstract:

92 Background: Immunotherapy (IO) can lead to immune-related adverse events (irAEs). Evidence on the association of irAEs and efficacy is limited. Methods: We conducted a systematic review in MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (inception to July 1, 2019) to identify randomized controlled trials (RCTs) reporting irAEs, incidence and efficacy data for pembrolizumab (PEM), nivolumab (NIVO), ipilimumab (IPI), atezolizumab, avelumab, durvalumab, and aldesleukin in lung, renal, head and neck cancer, and melanomas. RCTs assessing IO monotherapy or IO combinations in a

APA, Harvard, Vancouver, ISO, and other styles

9

Liu, Can, Jonathan M. Snowden, Deirdre J. Lyell, et al. "Interpregnancy Interval and Subsequent Severe Maternal Morbidity: A 16-Year Population-Based Study From California." American Journal of Epidemiology 190, no. 6 (2021): 1034–46. http://dx.doi.org/10.1093/aje/kwab020.

Full text

Abstract:

Abstract Interpregnancy interval (IPI) is associated with adverse perinatal outcomes, but its contribution to severe maternal morbidity (SMM) remains unclear. We examined the association between IPI and SMM, using data linked across sequential pregnancies to women in California during 1997–2012. Adjusting for confounders measured in the index pregnancy (i.e., the first in a pair of consecutive pregnancies), we estimated adjusted risk ratios for SMM related to the subsequent pregnancy. We further conducted within-mother comparisons and analyses stratified by parity and maternal age at the index

APA, Harvard, Vancouver, ISO, and other styles

10

Gebremedhin, Amanuel Tesfay, Gizachew Assefa Tessema, Annette K. Regan, and Gavin F. Pereira. "Association between interpregnancy interval and pregnancy complications by history of complications: a population-based cohort study." BMJ Open 11, no. 12 (2021): e046962. http://dx.doi.org/10.1136/bmjopen-2020-046962.

Full text

Abstract:

ObjectiveTo examine if the association between interpregnancy interval (IPI) and pregnancy complications varies by the presence or absence of previous complications.Design and settingPopulation-based longitudinally linked cohort study in Western Australia (WA).ParticipantsMothers who had their first two (n=252 368) and three (n=96 315) consecutive singleton births in WA between 1980 and 2015.Outcome measuresWe estimated absolute risks (AR) of preeclampsia (PE) and gestational diabetes (GDM) for 3–60 months of IPI according to history of each outcome. We modelled IPI using restricted cubic spli

APA, Harvard, Vancouver, ISO, and other styles

11

Borzillo, Valentina, Rossella Di Franco, Diana Giannarelli, et al. "Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience." Cancers 13, no. 8 (2021): 1857. http://dx.doi.org/10.3390/cancers13081857.

Full text

Abstract:

The median overall survival (OS) and local control (LC) of patients with melanoma brain metastases (MBMs) are poor even with immune checkpoint inhibitors and/or radiotherapy (RT). The aims of the study were to evaluate the association and timing of stereotactic radiotherapy (SRT)/radiosurgery (SRS) performed with the CyberKnife® System and ipilimumab (IPI). A total of 63 MBMs patients were analyzed: 53 received RT+IPI and 10 RT alone. Therefore, the patients were divided into four groups: RT PRE-PI (>4 weeks before IPI) (18), RT CONC-IPI (4 weeks before/between first and last cycle/within 3

APA, Harvard, Vancouver, ISO, and other styles

12

Kurata, Nicole B., Keith K. Ogasawara, Kathryn L. Pedula, and William A. Goh. "Prolonged interpregnancy interval: how does it impact the length of second stage of labor?" Journal of Perinatal Medicine 48, no. 8 (2020): 811–18. http://dx.doi.org/10.1515/jpm-2020-0171.

Full text

Abstract:

AbstractObjectivesShort interpregnancy intervals (IPI) have been linked to multiple adverse maternal and neonatal outcomes, but less is known about prolonged IPI, including its relationship with labor progression. The objective of the study was to investigate whether prolonged IPIs are associated with longer second stages of labor.MethodsA perinatal database from Kaiser Permanente Hawaii was used to identify 442 women with a prolonged IPI ≥60 months. Four hundred forty two nulliparous and 442 multiparous women with an IPI 18–59 months were selected as comparison groups. The primary outcome was

APA, Harvard, Vancouver, ISO, and other styles

13

Allayous, Clara, Stéphane Dalle, Marie Thérèse Leccia, et al. "Role of time to switch from ipilimumab to anti-PD1 in anti-PD1 efficacy within the French national cohort, MelBase." Journal of Clinical Oncology 35, no. 15_suppl (2017): 9551. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9551.

Full text

Abstract:

9551 Background: With increasing armamentarium in advanced melanoma management, the impact of various strategies remains to be determined including the importance of time to switch from one treatment to another. We report the impact of time to IPI/APD non-planned switch on APD efficacy in real life patients within MelBase (MB). Methods: MB is a French multicentric biobank dedicated to the prospective follow-up (FU) of unresectable stage III or IV melanoma with 1102 patients included since March 2013. Data were collected (Sept.2016) and analyzed (demography, overall survival (OS), progression-f

APA, Harvard, Vancouver, ISO, and other styles

14

Matar, Sayed, Opeyemi Jegede, Thomas Denize, et al. "Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial." Journal of Clinical Oncology 42, no. 16_suppl (2024): 4536. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.4536.

Full text

Abstract:

4536 Background: We have previously shown that levels of antigen-experienced but not terminally exhausted CD8+ TILs (i.e. CD8+PD1+TIM3-LAG3- TILs) are associated with improved clinical outcomes in patients (pts) with metastatic clear cell RCC (mccRCC) treated with nivolumab monotherapy within three independent clinical trials (CheckMate-010, CheckMate-025, HCRN GU16-260). Here, we aimed to evaluate the performance of this biomarker in patients with mccRCC treated with nivolumab plus ipilimumab (Nivo+Ipi) versus sunitinib (Sun) as part of the CheckMate-214 (CM-214) clinical trial. Methods: Pre-

APA, Harvard, Vancouver, ISO, and other styles

15

Kim, Min Kyeong, Hyeon Seok Eom, Hyewon Lee, et al. "Adverse Prognostic Impact of Vascular Endothelial Growth Factor Gene Polymorphism in Patients with Non-Hodgkin Lymphoma." Blood 120, no. 21 (2012): 2674. http://dx.doi.org/10.1182/blood.v120.21.2674.2674.

Full text

Abstract:

Abstract Abstract 2674 Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis and progression of many types of cancer, and VEGF expression has been known to be associated with polymorphism of gene. However, the impact of polymorphisms of the VEGF gene on non-Hodgkin lymphoma (NHL) prognosis has not been fully elucidated. Here we investigated the association between VEGF polymorphisms and prognosis of NHL. The study involved 96 NHL patients treated at National Cancer Center, Korea. The median patient age was 57 years, and 60 patients (62.5%) were men. A total of 5 pol

APA, Harvard, Vancouver, ISO, and other styles

16

Tarhini, Ahmad A., Sandra J. Lee, Ni Kang, et al. "Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of hormone replacement and immunosuppressants, and association with outcome: E1609 study analysis." Journal of Clinical Oncology 38, no. 5_suppl (2020): 60. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.60.

Full text

Abstract:

60 Background: E1609 evaluated adjuvant ipilimumab at 3 mg/kg (ipi3) and 10 mg/kg (ipi10) versus high-dose interferon-α (HDI). In-depth analysis of irAEs and the use of immunosuppressants and hormone replacement may provide important lessons for management and future research. Methods: E1609 enrolled 1670 adult pts with resected cutaneous melanoma (AJCC7 IIIB, IIIC, M1a, M1b); Table. We investigated the characteristics of irAEs, corticosteroid, immunosuppressant and hormone use on the ipi arms and association with outcome. Stratified log-rank test was used and since most irAEs were observed wi

APA, Harvard, Vancouver, ISO, and other styles

17

Tessema, Gizachew A., M. Luke Marinovich, Siri E. Håberg, et al. "Interpregnancy intervals and adverse birth outcomes in high-income countries: An international cohort study." PLOS ONE 16, no. 7 (2021): e0255000. http://dx.doi.org/10.1371/journal.pone.0255000.

Full text

Abstract:

Background Most evidence for interpregnancy interval (IPI) and adverse birth outcomes come from studies that are prone to incomplete control for confounders that vary between women. Comparing pregnancies to the same women can address this issue. Methods We conducted an international longitudinal cohort study of 5,521,211 births to 3,849,193 women from Australia (1980–2016), Finland (1987–2017), Norway (1980–2016) and the United States (California) (1991–2012). IPI was calculated based on the time difference between two dates—the date of birth of the first pregnancy and the date of conception o

APA, Harvard, Vancouver, ISO, and other styles

18

Chesney, Jason Alan, Igor Puzanov, Frances A. Collichio, et al. "Association between complete response and survival in advanced melanoma treated with talimogene laherparepvec (T-VEC) plus ipilimumab (ipi)." Journal of Clinical Oncology 38, no. 15_suppl (2020): 10029. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.10029.

Full text

Abstract:

10029 Background: This is the first randomized trial testing the addition of an oncolytic virus to an immune checkpoint inhibitor for advanced melanoma. At the 3-year (yr) follow-up, the combination (combo) of T-VEC and ipi demonstrated durable and statistically superior objective response rate (ORR) over ipi alone (36.7% vs. 16.0%; odds ratio, 3.0; 95% Cl, 1.6–6.0; P = 0.002). Complete response (CR) rate was 21.4% with the combo and 6.0% with ipi. Median overall survival (OS) was not reached in either arm. In this post hoc analysis, we utilized the 3-yr landmark data to explore the relationsh

APA, Harvard, Vancouver, ISO, and other styles

19

Sussman, Tamara A., Joanna Roopkumar, Hong Li, Brian Hobbs, Alok A. Khorana, and Pauline Funchain. "Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO)." Journal of Clinical Oncology 38, no. 5_suppl (2020): 94. http://dx.doi.org/10.1200/jco.2020.38.5_suppl.94.

Full text

Abstract:

94 Background: VTE in cancer significantly contributes to morbidity and a worse overall prognosis. Little is known about the incidence of VTE in melanoma pts receiving IO. This study aims to assess the incidence of VTE in melanoma pts on IO, interrogate potential association with specific therapies, and ascertain its prognostic utility. Methods: We conducted a retrospective cohort study of melanoma pts who received any IO including ipilimumab (ipi), nivolumab (nivo) or pembrolizumab (pembro) from July 2015 to December 2017 at the Cleveland Clinic. VTE including deep venous thrombosis and pulmo

APA, Harvard, Vancouver, ISO, and other styles

20

Shi, Qing, Rong Shen, Chao-Fu Wang, et al. "Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients." Mediators of Inflammation 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/7960907.

Full text

Abstract:

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of lymphoma, with different clinical manifestation and prognosis. The International Prognostic Index (IPI), an index designed during the prerituximab era for aggressive lymphoma, showed variable values in the prediction of patient clinical outcomes. The aim of this study was to analyze the prognostic value and causes of pretreatment liver injury in 363 de novo DLBCL patients in our institution. Pretreatment liver impairment, commonly detected in lymphoma patients, showed significant association with poor outcomes and increased seru

APA, Harvard, Vancouver, ISO, and other styles

21

Rodig, Scott, Daniel Gusenleitner, Donald Jackson, et al. "Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064." Journal of Clinical Oncology 35, no. 15_suppl (2017): 9515. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9515.

Full text

Abstract:

9515 Background: CheckMate 064 (open label, phase 2) randomized advanced melanoma pts to NIVO 3 mg/kg Q2W for 6 doses then IPI 3 mg/kg Q3W for 4 doses (n = 70; cohort A), or the reverse (IPI then NIVO; n = 70; cohort B). More cohort A than cohort B pts had complete or partial response (54% and 31%, respectively). We sought to determine whether common or distinct baseline biomarkers were associated with response for each cohort. Methods: Protein expression of biomarkers identifying a broad array of cell lineages and immunoregulatory factors was determined by IHC and evaluated by 2 pathologists,

APA, Harvard, Vancouver, ISO, and other styles

22

Ahlers-Schmidt, Carolyn R., Nikki Keene Woods, Danielle Bradshaw, Anna Rempel, Matt Engel, and Mary Benton. "Maternal Knowledge, Attitudes, and Practices Concerning Interpregnancy Interval." Kansas Journal of Medicine 11, no. 4 (2018): 86–90. http://dx.doi.org/10.17161/kjm.v11i4.8703.

Full text

Abstract:

Introduction. Few studies have examined maternal intentions andpractices related to interpregnancy interval (IPI). IPI less than 18months has been linked to increased preterm birth and infant mortality.This manuscript reports on a cross-sectional survey of mothersconducted to understand maternal knowledge, attitudes, and practiceof IPI in Sedgwick County, Kansas. Methods. New and expectant mothers and mothers of neonatalinfant care unit (NICU) graduates (n = 125) were surveyed regardingthe issues surrounding IPI. Front desk staff handed out self-administeredsurveys, which were returned t

APA, Harvard, Vancouver, ISO, and other styles

23

Harding, James J., Mario E. Lacouture, Melissa Pulitzer, et al. "Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy." Journal of Clinical Oncology 30, no. 15_suppl (2012): 8515. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.8515.

Full text

Abstract:

8515 Background: Ipilimumab (IPI) and vemurafenib (VEM) each improve overall survival for patients (pts) with metastatic melanoma. Both are FDA-approved and are being used in pts with BRAFV600E-mutated metastatic melanoma. We previously described cases of prominent skin eruptions associated with VEM in pts who had previously received IPI. Methods: We have updated our experience of BRAFV600E-mutated melanoma pts treated with VEM who had previously received IPI. Pts were treated at our center from January 2007 to January 2012. Data were collected under an approved IRB waiver. Results: Sixteen me

APA, Harvard, Vancouver, ISO, and other styles

24

Lee, Shin, Negoro Eiju, Morishita Tetsuji, et al. "The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index." Blood 134, Supplement_1 (2019): 2902. http://dx.doi.org/10.1182/blood-2019-121527.

Full text

Abstract:

Background Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL featured by rapid progression. Given its rapid progression, prompt diagnosis and treatment are essential for achieving long-term survival in DLBCL. In solid cancers, it is known that prolonging diagnostic wait time (DWT), interval from diagnosis to initiation of treatment, could result in stage progression and a worse survival. In DLBCL patients, a prolonged DWT is also expected to be associated with a worse survival, however, little is known about this issue. The purpose of this investigation was to verify the imp

APA, Harvard, Vancouver, ISO, and other styles

25

Hermansyah, Muhammad. "Business Coaching Bagi Calon Karyawan Gerai Ikatan Pesantren Indonesia di Wilayah Provinsi Jawa Timur." Humanist Journal 2, no. 2 (2025): 35–39. https://doi.org/10.59689/edyb5082.

Full text

Abstract:

The Indonesian Islamic Boarding Association encourages pesantren to address the problems they face on their own, rather than relying on government assistance that has not been able to attend for pesantren. So that through empowerment programs, Islamic boarding schools must be empowered, including through the IPI Outlet For Islamic Boarding Schools, which is one part of the program implemented in accordance with the 2020 IPI National Conference Amanah, namely through the Pesantren Economic Movement, including printing young students through the IPI Outlet. In carrying out this activity, first,

APA, Harvard, Vancouver, ISO, and other styles

26

Pina, Paulo, Elham Sabri, and Peter G. Lawlor. "Characteristics and Associations of Pain Intensity in Patients Referred to a Specialist Cancer Pain Clinic." Pain Research and Management 20, no. 5 (2015): 249–54. http://dx.doi.org/10.1155/2015/807432.

Full text

Abstract:

BACKGROUND: Uncontrolled cancer pain (CP) may impair quality of life. Given the multidimensional nature of CP, its poor control is often attributed to poor assessment and classification.OBJECTIVES: To determine the characteristics and associations of pain intensity in a specialist CP clinic.METHODS: Consecutive patients referred to the CP clinic of the Portuguese Cancer Institute (Lisbon, Portugal) had standardized initial assessments and status documentation of the following: Brief Pain Inventory ratings for ‘pain now’ as the outcome variable; initial pain intensity (iPI) on a 0 to 10 scale;

APA, Harvard, Vancouver, ISO, and other styles

27

Batki, Isabella. "Exploring the Association Between Intimate Partner Violence and Short Interpregnancy Intervals [ID 1404]." Obstetrics & Gynecology 145, no. 6S (2025): 57S. https://doi.org/10.1097/aog.0000000000005917.093.

Full text

Abstract:

INTRODUCTION: The objective was to evaluate if a history of intimate partner violence (IPV) increases risk of short interpregnancy interval (IPI) and to identify contributing factors. METHODS: A retrospective cohort study of records from initial obstetrical visits at an urban community-based hospital from July 2020 to February 2023 was performed. The study was IRB exempt. Primigravid patients and those who underwent artificial reproductive technology were excluded. Two groups were identified: those who endorsed IPV and those who did not. Outcomes included short IPI (less than 18 months between

APA, Harvard, Vancouver, ISO, and other styles

28

Zhong, Charlie, Jianning Luo, Chun R. Chao, et al. "Polygenic Risk Score in Follicular Lymphoma Risk and Prognosis in a Population-Based Case-Control Study in Los Angeles County." Blood 132, Supplement 1 (2018): 2296. http://dx.doi.org/10.1182/blood-2018-99-111947.

Full text

Abstract:

Abstract Background: Although several prognostic factors are regularly utilized for follicular lymphoma (FL) - e.g., extent of disease, presence of B-symptoms, and the FL international prognostic index (IPI) - they do not fully account for the heterogeneity in patient outcomes. Etiologic risk factors may influence the heterogeneity of prognostic outcomes, but relatively few risk factors for FL have been identified and subsequently confirmed. Recent epidemiologic studies have uncovered genetic risk loci associated with FL risk. To date, the association between these risk alleles with FL prognos

APA, Harvard, Vancouver, ISO, and other styles

29

Wang, Ze, Yueru Meng, Xue Shang, et al. "Interpregnancy Interval After Clinical Pregnancy Loss and Outcomes of the Next Frozen Embryo Transfer." JAMA Network Open 6, no. 10 (2023): e2340709. http://dx.doi.org/10.1001/jamanetworkopen.2023.40709.

Full text

Abstract:

ImportanceThe optimal interpregnancy interval (IPI) after a clinical pregnancy loss (CPL) remains controversial. Few studies have addressed the role of the IPI after a preceding CPL during in vitro fertilization (IVF) treatment.ObjectiveTo evaluate the association between different IPI lengths after a preceding CPL and pregnancy outcomes of the next frozen embryo transfer (FET).Design, Setting, and ParticipantsThis retrospective cohort study was conducted using data from the Center for Reproductive Medicine of Shandong University in China. The study included women who underwent frozen-thawed b

APA, Harvard, Vancouver, ISO, and other styles

30

Sharma, Padmanee, Michael Krainer, Fred Saad, et al. "Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial." Journal of Clinical Oncology 41, no. 6_suppl (2023): 22. http://dx.doi.org/10.1200/jco.2023.41.6_suppl.22.

Full text

Abstract:

22 Background: In preliminary analyses from the randomized phase 2, open-label CheckMate 650 trial, nivolumab (NIVO) 1 mg/kg (N1) plus ipilimumab (IPI) 3 mg/kg (I3) Q3W × 4 doses showed clinical activity in patients (pts) with post-chemotherapy (post-CT) mCRPC, particularly those with high tumor mutational burden (TMB), but early toxicity contributed to treatment discontinuations. Here, we report results from pts with post-CT mCRPC receiving alternative NIVO+IPI dosing regimens vs IPI alone vs cabazitaxel (CABA) in CheckMate 650. Methods: Newly enrolled pts previously treated with docetaxel fo

APA, Harvard, Vancouver, ISO, and other styles

31

Vemula, Sai Vikram, Wenxin Xu, Yu Wang, et al. "Abstract 5151: High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma." Cancer Research 84, no. 6_Supplement (2024): 5151. http://dx.doi.org/10.1158/1538-7445.am2024-5151.

Full text

Abstract:

Abstract Introduction: CheckMate 914 (CM-914) Part A is a double-blind, phase III randomized trial of the Nivolumab (NIVO) plus Ipilimumab (IPI) vs placebo (PBO) in localized ccRCC. Our prior report from this study suggested a disease-free survival (DFS) benefit for NIVO+IPI among patients with Fuhrman grade 4, TNM stages PT2a and PT4, or sarcomatoid features, although the sample size was limited. It is known that high circulating KIM-1 is associated with worse DFS after nephrectomy. In this exploratory post hoc analysis, we investigated whether high KIM-1 may help identify a subset of patient

APA, Harvard, Vancouver, ISO, and other styles

32

Chen, Yu-Wei, Matthew D. Tucker, Landon C. Brown, et al. "The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma." Cancers 14, no. 15 (2022): 3830. http://dx.doi.org/10.3390/cancers14153830.

Full text

Abstract:

A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/nivolumab (ipi/nivo) initiation and treatment responses in mRCC. A retrospective study of ipi/nivo-treated mRCC at two US academic cancer centers was conducted. A landmark analysis at week 6 was performed to assess the association between the change in NER and clinical responses (progression-free survival (PFS)/overall survival (OS)). Week 6 N

APA, Harvard, Vancouver, ISO, and other styles

33

Nadia, Agnes, Syamsul Bihar, and Fajrinur Syarani. "Hubungan Antara Pola Kuman dengan Mortalitas pada Pasien Pneumonia di IPI RS. HAM Medan." Public Health and Safety International Journal 5, no. 01 (2025): 92–97. https://doi.org/10.55642/phasij.v5i01.990.

Full text

Abstract:

Pneumonia is one of the leading causes of morbidity and mortality, partIPIlarly in hospital settings. Identifying bacterial patterns and antibiotic resistance is essential to determine appropriate therapy and reduce mortality rates. This study aimed to examine the association between bacterial patterns, antibiotic resistance, and mortality in pneumonia patients. A retrospective design was used by analyzing medical record data of pneumonia patients treated in 2022. A total of 66 patients who met the inclusion criteria were included in the analysis. Data included sputum culture results, antibiot

APA, Harvard, Vancouver, ISO, and other styles

34

Doma, Andrej, Andrej Studen, and Barbara Jezeršek Novaković. "Prognostic Value of Multiple Manual Segmentation Methods for Diffuse Large B-Cell Lymphoma with 18F-FDG PET/CT." Current Oncology 32, no. 6 (2025): 356. https://doi.org/10.3390/curroncol32060356.

Full text

Abstract:

Quantitative 18F-FDG PET/CT-derived metabolic metrics are strongly associated with patient outcomes in diffuse large B-cell lymphoma (DLBCL), but the lack of consensus on optimal segmentation thresholds limits standardization. This study evaluated the prognostic value of various metabolic tumor volume (MTV) segmentation approaches in 140 stage II–IV DLBCL patients treated with standard immunochemotherapy. MTV was derived using fixed SUV (≥2.5, ≥4.0), relative (>41% SUVmax), and adaptive (liver-to-background) thresholds. Baseline MTV metrics significantly correlated with 3-year overall survi

APA, Harvard, Vancouver, ISO, and other styles

35

Xu, Wenxin, Sai Vikram Vemula, Robert J. Motzer, et al. "Evaluation of circulating kidney injury marker-1 (KIM-1) as a prognostic and predictive biomarker in advanced renal cell carcinoma (aRCC): Post-hoc analysis of CheckMate 214." Journal of Clinical Oncology 43, no. 5_suppl (2025): 437. https://doi.org/10.1200/jco.2025.43.5_suppl.437.

Full text

Abstract:

437 Background: CheckMate 214 established nivolumab and ipilimumab (NIVO+IPI) as a first line standard of care regimen with superior survival and durable response versus sunitinib (SUN) in advanced RCC. Previous studies have shown that high levels of circulating KIM-1 are associated with worse prognosis and reduction in KIM-1 levels is associated with benefit from adjuvant immunotherapy. In this post-hoc analysis we evaluated whether KIM-1 levels at baseline and after 1 cycle of NIVO+IPI or SUN are associated with treatment outcomes in CheckMate 214. Methods: Patients with advanced RCC were ra

APA, Harvard, Vancouver, ISO, and other styles

36

Brito, Angelo Borsarelli Carvalho, Cristiane Oliveira, Marcia Toressan Delamain, Carmino Antonio De Souza, José Vassallo, and Carmen Silvia Passos Lima. "Association of Bax and Bcl-2 polymorphisms in Aggressiveness and Prognosis of Diffuse Large B-Cell Lymphoma." Blood 124, no. 21 (2014): 3017. http://dx.doi.org/10.1182/blood.v124.21.3017.3017.

Full text

Abstract:

Abstract Background: Apoptosis, with participation of the pro-apoptotic BAX and the anti-apoptotic BCL-2 proteins, plays a key role in outcome of patients with diffuse large B cell lymphoma (DLBCL). The ability to induce apoptosis is variable in humans, since several proteins enrolled in the process are encoded by polymorphic genes. The G wild allele of the BAX G(-248)A and the variant A allele of the BCL2 C(-717)A single nucleotide polymorphisms (SNPs) are related to lower transcriptional activity and higher BCL-2 protein expression, respectively, compared to the A variant and the C wild alle

APA, Harvard, Vancouver, ISO, and other styles

37

Kleinstern, Geffen, Daniel R. O'Brien, Brian Kabat, et al. "Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)." Blood 134, Supplement_1 (2019): 852. http://dx.doi.org/10.1182/blood-2019-124346.

Full text

Abstract:

Background The CLL international prognostic index (CLL-IPI) is a validated staging system for newly diagnosed CLL patients that combines age, clinical stage, serum Beta-2 microglobulin, TP53, and IGHV mutation status into a single score and stratifies CLL patients into four prognostic risk groups with a c-statistic=0.72. Next-generation sequencing identified ~60 putative driver genes recurrently mutated in CLL, and genome-wide association studies (GWAS) identified 41 single nucleotide polymorphisms (SNPs) associated with CLL risk. We previously showed that a polygenic risk score (PRS) of the w

APA, Harvard, Vancouver, ISO, and other styles

38

Getahun, Darios, In-Lu Amy Liu, Lina S. Sy, et al. "Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies." JAMA Network Open 7, no. 9 (2024): e2434857. http://dx.doi.org/10.1001/jamanetworkopen.2024.34857.

Full text

Abstract:

ImportanceAlthough influenza vaccination has been found to be safe in pregnancy, few studies have assessed repeated influenza vaccination over successive pregnancies, including 2 vaccinations in a year, in terms of adverse perinatal outcomes.ObjectiveTo examine the association of seasonal influenza vaccination across successive pregnancies with adverse perinatal outcomes and whether the association varies by interpregnancy interval (IPI) and vaccine type (quadrivalent or trivalent).Design, Setting, and ParticipantsThis retrospective cohort study included individuals with at least 2 successive

APA, Harvard, Vancouver, ISO, and other styles

39

Masar, Michal, Prokop Vodicka, Samuel Hricko, et al. "Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World." Blood 144, Supplement 1 (2024): 3081. https://doi.org/10.1182/blood-2024-208592.

Full text

Abstract:

Introduction CNS relapse in diffuse large B-cell lymphoma (DLBCL) is a rare, but mostly fatal event. The CNS International Prognostic Index (CNS-IPI) represents widely adopted prognostic model. As previously shown, there is a different CNS relapse rate in different subgroups defined by gene expression profiling (GEP; GCB vs ABC; Klanova, 2019), as well as higher frequency of distinct molecular subtypes (MCD) among patients (pts) who developed CNS relapses (Ollila, 2021). Integration of COO by GEP into the CNS-IPI led to a modified prognostic CNS-IPI-C model (one point for high CNS-IPI, and one

APA, Harvard, Vancouver, ISO, and other styles

40

Göçlü, Fatma, Hatice Terzi, Neşe Yeldir, and Mehmet Şencan. "Epstein-Barr virus RNA percentage and its impact on prognosis in patients with diffuse large B-cell lymphoma." Intercontinental Journal of Internal Medicine 3, no. 1 (2025): 15–18. https://doi.org/10.51271/icjim-0050.

Full text

Abstract:

Aims: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas. This study aimed to investigate the impact of Epstein-Barr virus RNA (EBER) positivity on the prognosis of patients diagnosed with DLBCL. Methods: This retrospective study was conducted on 105 patients diagnosed with DLBCL at Sivas Cumhuriyet University Hospital between June 1, 2009, and May 31, 2022. Results: Of the 105 patients, 55.2% were male, and the mean age was 56.89 years. EBER positivity was detected in 4.8% of the patients. While 71% of EBER-negative patients achieved a complete response,

APA, Harvard, Vancouver, ISO, and other styles

41

Kong, Sun-Young, Hyewon Lee, Ji Yeon Sohn, and Hyeon-Seok Eom. "Adverse Prognostic Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Diffuse Large B Cell Lymphoma." Blood 124, no. 21 (2014): 5410. http://dx.doi.org/10.1182/blood.v124.21.5410.5410.

Full text

Abstract:

Abstract Neutrophil-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been lightened as a prognostic factor in many types of solid tumor. However, there was a limited report for diffuse large B cell lymphoma (DLBCL). Thus, we investigated the impact of NLR and PLR on prognosis of patients with DLBCL. This study involved 234 DLBCL patients treated by rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) at National Cancer Center, Korea. The median patient age was 57 years, and 135 patients (58%) were men. Clinical characteristics as international

APA, Harvard, Vancouver, ISO, and other styles

42

Hodi, F. Stephen, Vanna Chiarion-Sileni, Rene Gonzalez, et al. "Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067." Journal of Clinical Oncology 41, no. 16_suppl (2023): 9542. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.9542.

Full text

Abstract:

9542 Background: NIVO + IPI has demonstrated durable clinical benefit at 7.5 y in pts with advanced melanoma in the phase 3 CheckMate 067 study. PFS curves plateaued at ~3 y in this study, suggesting that being alive and progression-free for ≥ 3 y (PFS ≥ 3y) may be a good surrogate for long-term clinical benefit. We conducted analyses to quantify this association. Methods: Pts with treatment (tx)-naive, unresectable stage III/IV melanoma (stratified by PD-L1 expression, BRAF mutation status, and metastasis stage) received NIVO 1 mg/kg + IPI 3 mg/kg for 4 doses Q3W, followed by NIVO 3 mg/kg Q2W

APA, Harvard, Vancouver, ISO, and other styles

43

Gujo, Amelo Bolka, Assefa Philipos Kare, and Shambel Gussa Shuramo. "Intestinal Parasite Infection and Its Association with Undernutrition among Early Adolescents in Hawassa University Technology Village, Southern Ethiopia." Advances in Public Health 2021 (October 15, 2021): 1–9. http://dx.doi.org/10.1155/2021/3937948.

Full text

Abstract:

Background. Different studies presented negating findings of the association between intestinal parasite infections (IPIs) and undernutrition among early adolescents in Ethiopia. This study was aimed at assessing intestinal parasite infection and its association with undernutrition among early adolescents in four selected districts of the Sidama region. Method. An institution-based cross-sectional study was conducted in October 2020 among 792 early adolescents. The multistage stage sampling was applied to select 16 primary schools. Simple random sampling was applied to select study participant

APA, Harvard, Vancouver, ISO, and other styles

44

Vanderwalde, Ari M., James Moon, Kari Kendra, et al. "Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy." Cancer Research 82, no. 12_Supplement (2022): CT013. http://dx.doi.org/10.1158/1538-7445.am2022-ct013.

Full text

Abstract:

Abstract Background: Patients with advanced melanoma primarily refractory to single agent PD-1 blockade therapy have an option of receiving the CTLA-4 blocking antibody ipilimumab, but if ipilimumab should be given as a single agent or in combination with the anti-PD-1 nivolumab has not been established prospectively. Methods: Patients aged &gt;18 with metastatic or unresectable melanoma without objective response to anti-PD-1 therapy given without CTLA-4 therapy were randomized 3:1 to receive either ipilimumab 3mg/kg + nivolumab 1mg/kg q3 wks x4 cycles followed by nivolumab 480mg q4wks (i

APA, Harvard, Vancouver, ISO, and other styles

45

Wei, Cynthia, Sandra K. Althouse, Hirva Mamdani, Nasser H. Hanna, and Greg Andrew Durm. "Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non–small-cell lung cancer (NSCLC)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 8565. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.8565.

Full text

Abstract:

8565 Background: Immunotherapy has been widely incorporated into the treatment of patients with non-small-cell lung cancer. Many of these patients will experience immune-related adverse events (irAEs) that may lead to early discontinuation of therapy. Previous studies have reported that patients with Stage III and metastatic NSCLC who experienced irAEs receive fewer cycles of immunotherapy without decreased efficacy. Here we report a retrospective analysis of the association between irAEs and efficacy outcomes from the BTCRC LUN 16-081 randomized phase 2 trial of consolidation immunotherapy wi

APA, Harvard, Vancouver, ISO, and other styles

46

van Dorp, Jeroen, Christodoulos Pipinikas, Nick van Dijk, et al. "Abstract 1273: Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay." Cancer Research 82, no. 12_Supplement (2022): 1273. http://dx.doi.org/10.1158/1538-7445.am2022-1273.

Full text

Abstract:

Abstract Patients (pts) with stage III (cT3-4aN0M0 or cT1-4aN1-3M0) urothelial cancer (UC) have a poor prognosis. In NABUCCO cohort 1, 24 stage III UC pts were treated with ipilimumab (ipi) plus nivolumab (nivo) followed by radical surgery (day 1: ipi 3 mg/kg; day 22: ipi 3 mg/kg + nivo 1 mg/kg; day 43: nivo 3 mg/kg). 14/24 (58%) of pts showed a pathological response (ypT0N0 or ypTisN0/ypTaN0). Currently, there are no good biomarkers to assess response before surgery, potentially leading to overtreatment and unnecessary surgical complications. Here, we investigated whether detection of circula

APA, Harvard, Vancouver, ISO, and other styles

47

Yhim, Ho-Young, Yong Park, Joon Ho Moon, et al. "Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas." Blood 132, Supplement 1 (2018): 1657. http://dx.doi.org/10.1182/blood-2018-99-115620.

Full text

Abstract:

Abstract Background Nodal peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of neoplasms, which include PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large-cell lymphoma-anaplastic lymphoma kinase positive (ALCL, ALK-pos), and ALCL, ALK-neg. International prognostic index (IPI) is a widely used tool for risk stratification and has shown a strong association with survival in nodal PTCL. The prognostic index for PTCL-U (PIT) is a specific prognostication tool for PTCL and has also shown prognostic relevance in nodal PTCL. The National

APA, Harvard, Vancouver, ISO, and other styles

48

Huber, Fabian, Elisabeth Zwickl-Traxler, Martin Pecherstorfer, and Josef Singer. "Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma—A Single-Center Retrospective Cohort Study." Current Oncology 28, no. 6 (2021): 4521–29. http://dx.doi.org/10.3390/curroncol28060383.

Full text

Abstract:

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and prognostic information is essential in finding the right treatment. This study evaluated the prognostic significance of Ki-67 in patients with DLBCL. Methods: Patients with DLBCL, treated with first-line R-CHOP, were retrospectively analyzed in groups of high (>70%) and low (≤70%) Ki-67. Parameters of interest were the international prognostic index (IPI), treatment response, progression-free survival (PFS) and overall survival (OS). A chi-squared test or Fisher’s exact test was conducted to analyz

APA, Harvard, Vancouver, ISO, and other styles

49

Liu, TingBo, LiHong Chen, Jie Pan, LiLi Pan, JianDa Hu, and ZhongYou Ji. "Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography." Acta Haematologica 139, no. 3 (2018): 148–57. http://dx.doi.org/10.1159/000479486.

Full text

Abstract:

Background: The International Prognostic Index (IPI) scoring system is the most widely used prognostic tool for diffuse large B-cell lymphoma (DLBCL); however, it fails to consistently identify patients with poor outcomes. This retrospective study was undertaken to confirm the clinical value of a new prognostic score and compare it with the IPI. Methods: The aim of this single-center study was to confirm the clinical value of a new prognostic score and its association with various clinical features, disease progression, and death in 70 patients with DLBCL who had undergone at least 6 cycles of

APA, Harvard, Vancouver, ISO, and other styles

50

Esteves Domingues Pires da Silva, Ines, Jordan W. Conway, Akshaya Ramanathan, et al. "Distinct effect of neoadjuvant PD1 alone, PD1+IPI, and PD1+lenvatinib in the peripheral immune profile of melanoma patients (pts) and correlation with pathological (path) response." Journal of Clinical Oncology 43, no. 16_suppl (2025): 9568. https://doi.org/10.1200/jco.2025.43.16_suppl.9568.

Full text

Abstract:

9568 Background: Neoadjuvant immunotherapy (NeoIT) has significantly improved clinical outcomes for pts with macroscopic stage III resectable melanoma and is the current standard of care for these pts. Here, we analysed longitudinal peripheral immune profiles and their correlation with path response for 3 different PD1-based NeoIT regimens. Methods: Pts with macroscopic stage III resectable melanoma treated with neoadjuvant PD1-based regimens (PD1 alone, PD1+IPI and PD1+Lenvatinib) for 6 weeks, followed by surgery, were included. Cytometry by time-of-flight (CYTOF; 39-marker panel) was perform

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!